GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theseus Pharmaceuticals Inc (NAS:THRX) » Definitions » Capex-to-Operating-Income

Theseus Pharmaceuticals (Theseus Pharmaceuticals) Capex-to-Operating-Income : 0.00 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Theseus Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Theseus Pharmaceuticals's Capital Expenditure for the three months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-16.40 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Theseus Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Theseus Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theseus Pharmaceuticals Capex-to-Operating-Income Chart

Theseus Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Income
- - - -

Theseus Pharmaceuticals Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Theseus Pharmaceuticals's Capex-to-Operating-Income

For the Biotechnology subindustry, Theseus Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theseus Pharmaceuticals's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theseus Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Theseus Pharmaceuticals's Capex-to-Operating-Income falls into.



Theseus Pharmaceuticals Capex-to-Operating-Income Calculation

Theseus Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.455) / -54.086
=N/A

Theseus Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -16.403
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theseus Pharmaceuticals  (NAS:THRX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Theseus Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Theseus Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Theseus Pharmaceuticals (Theseus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, Cambridge, MA, USA, 02142
Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.
Executives
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Foresite Capital Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradford D. Dahms officer: Chief Financial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Timothy P Clackson director, officer: President and CEO C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Steven H Stein director 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Foresite Capital Opportunity Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Opportunity Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
James B. Tananbaum 10 percent owner 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
William Shakespeare officer: See Remarks 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp 10 percent owner 190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022